Anti-IL23α Neutralizing Antibody

Catalog #
101453
$335 *
Size: 50 µg
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

This anti-IL23α (interleukin 23 subunit alpha) is a purified recombinant monoclonal antibody that selectively binds to the p19 subunit of heterodimeric IL-23, which is composed of p19 and IL-12 p40. This antibody has been tested for specific binding affinity to IL23α/IL12β antigen.

Synonyms
Risankizumab, Interleukin-23 subunit alpha, IL-23 subunit alpha; IL-23-A, Interleukin-23 subunit p19 (IL-23p19), IL23A, SGRF, UNQ2498/PRO5798
Product Info
Storage and Usage
Citations
Species
Human
Isotype
IgG1
Clonality
Monoclonal
Host Species/Expression System
HEK293
Purity

≥90%

Format

Aqueous buffer solution

Formulation

8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol

MW
Heavy Chain: 49 kDa; Light Chain: 24 kDa
UniProt #
Q9NPF7
Background

IL23 (interleukin 23) is a cytokine of the IL12 cytokine family. It is a heterodimeric cytokine with an IL-12p40 subunit and a p19 one. It is produced by macrophages and dendritic cells, and acts as a pro-inflammatory cytokine. It acts on memory T cells, leading to IFNγ (interferon gamma) and IL17 production, and Th17 (T helper type 17) cell proliferation. IL23 is involved in auto-immune and inflammatory disorders, such as psoriasis and arthritis. The use of IL23 targeting antibodies has been ongoing. Ustekinumab, commercialized under the name Stelara™, is one example of the benefits of disrupting the interaction between IL23 and its receptor can be beneficial in the treatment of autoimmune disorders.